{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:27:55Z","timestamp":1781076475515,"version":"3.54.1"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00444"],"award-info":[{"award-number":["PI21\/00444"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background and purpose<\/jats:title><jats:p>Screening for and treatment of latent tuberculosis (TB) in patients with end-stage kidney disease (ESKD) are recommended. However, there is limited evidence on safety and treatment completion in this population. The objective of the study is to evaluate three short-course rifamycin-based regimens for the treatment of latent TB in ESKD patients.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p><jats:bold>Study design and setting<\/jats:bold>. This is a prospective, open label, randomized clinical trial, that will be conducted at seven teaching hospitals in Spain.<\/jats:p><jats:p><jats:bold>Study population, randomization, and interventions<\/jats:bold>. Consecutive adult patients with ESKD requiring treatment for a latent TB infection will be randomly allocated (1:1:1) to receive one of the three treatment regimens of the study: three months of daily isoniazid plus rifampicin (3HR); three months of once-weekly isoniazid plus rifapentine (3HP); or four months of daily rifampicin (4R). Participants will be followed regularly through pre-established visits and a blood test schedule from enrolment to a month after finishing the assigned treatment.<\/jats:p><jats:p><jats:bold>Outcomes<\/jats:bold>. The primary outcome will be treatment completion, while the secondary outcomes will be discontinuation of the assigned treatment due to adverse events, related or unrelated to the study treatment; definitive discontinuation of the assigned treatment because of adverse events related to the treatment of the study, and death.<\/jats:p><jats:p><jats:bold>Sample size<\/jats:bold>. Two hundred and twenty-five subjects (75 per arm) will be enrolled, which will enable the demonstration, if it exists, of an increase of 0.16 in treatment completion rates either in the 3HP or 4R arm with respect to the 3HR arm.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Discussion<\/jats:title><jats:p>Results of this clinical trial will contribute to evidence-based recommendations on the management of latent TB infection in ESKD patients.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov identifier:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05021731\" xlink:type=\"simple\">NCT05021731<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0276387","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T17:25:52Z","timestamp":1666373152000},"page":"e0276387","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial)"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-3543","authenticated-orcid":true,"given":"Miguel","family":"Santin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Perez-Recio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Grijota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-6320","authenticated-orcid":true,"given":"Luis","family":"Anibarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Barcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"De Souza-Galvao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Gijon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the RIFAKiD team trial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"9979","key":"pone.0276387.ref001","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new End TB Strategy","volume":"385","author":"M Uplekar","year":"2015","journal-title":"Lancet"},{"key":"pone.0276387.ref002","first-page":"347103","article-title":"Mycobacterium tuberculosis infection following kidney transplantation","volume":"2013","author":"Toegel. F","year":"2013","journal-title":"Biomed Res Int"},{"issue":"4","key":"pone.0276387.ref003","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1183\/09031936.00000712","article-title":"The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement","volume":"40","author":"D Bumbacea","year":"2012","journal-title":"Eur Respir J"},{"issue":"9","key":"pone.0276387.ref004","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1097\/TP.0000000000001224","article-title":"Prevention and management of tuberculosis in transplant recipients: from guidelines to clinical practice","volume":"100","author":"L Mu\u00f1oz","year":"2016","journal-title":"Transplantation"},{"issue":"7","key":"pone.0276387.ref005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/TP.0b013e3181ecea8d","article-title":"Tuberculosis in Renal Transplant Recipients: The Evidence for Prophylaxis","volume":"90","author":"AC Currie","year":"2010","journal-title":"Transplantation"},{"issue":"6","key":"pone.0276387.ref006","doi-asserted-by":"crossref","first-page":"e13178","DOI":"10.1111\/tid.13178","article-title":"Treatment of latent TB infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review","volume":"21","author":"CLR Abad","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"pone.0276387.ref007","doi-asserted-by":"crossref","first-page":"e13603","DOI":"10.1111\/tid.13603","article-title":"Tuberculosis prevention in patients undergoing kidney transplantation: A nurse-led program for screening and treatment","author":"MD Grijota-Camino","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"pone.0276387.ref008","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/TP.0000000000001329","article-title":"Twelve-Week Rifapentine Plus Isoniazid versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates","volume":"101","author":"J Simkins","year":"2017","journal-title":"Transplantation"},{"issue":"2","key":"pone.0276387.ref009","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/TP.0b013e3182a94a2f","article-title":"Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates","volume":"97","author":"DL de Castilla","year":"2014","journal-title":"Transplantation"},{"issue":"3","key":"pone.0276387.ref010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s15010-017-1004-5","article-title":"Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates","volume":"45","author":"BM Knoll","year":"2017","journal-title":"Infection"},{"issue":"1","key":"pone.0276387.ref011","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jmii.2018.05.003","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection in haemodialysis patients: High rates of adverse events","volume":"52","author":"SY Lin","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"pone.0276387.ref012","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults","volume":"379","author":"D Menzies","year":"2018","journal-title":"N Engl J Med"},{"issue":"RR-1","key":"pone.0276387.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"TR Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"pone.0276387.ref014","unstructured":"Georgiev G.Z., \u201cSample Size Calculator\u201d. https:\/\/www.gigacalculator.com\/calculators\/power-sample-size-calculator.php [Accessed date: 2 February 2021]."},{"key":"pone.0276387.ref015","unstructured":"Cancer Therapy Evaluation Program. Common terminology for adverse events (CTAE), https:\/\/ctep.cancer.gov\/ [Accessed date: 2 February 2021]."},{"issue":"6","key":"pone.0276387.ref016","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of Latent Tuberculosis Infection. A Network Meta-analysis","volume":"161","author":"HR Stagg","year":"2014","journal-title":"Ann Intern Med"},{"issue":"23","key":"pone.0276387.ref017","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"the TB Trials Consortium PREVENT TB Study Team","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0276387.ref018","unstructured":"European Centre for Disease Prevention and Control. Programmatic management of latent tuberculosis infection in the European Union. Stockholm: ECDC; 2018. https:\/\/www.ecdc.europa.eu\/en\/tuberculosis\/prevention-and-control\/management-latent-tuberculosis-infection"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T10:31:55Z","timestamp":1701253915000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276387"}},"subtitle":[],"editor":[{"given":"Justyna","family":"Go\u0142\u0119biewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0276387","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}